After delays, court battles, Salix HIV diarrhea drug wins FDA OK
This article was originally published in Scrip
Executive Summary
The US FDA was not expected to give its verdict on Salix Pharmaceuticals' Fulyzaq (crofelemer) as a therapy to relieve symptoms of non-infectious diarrhea in patients with HIV/AIDS treated with antiretroviral treatments (ARTs) until the first quarter of 2013. But on the 31 December, regulators granted their OK – a decision that came after two delays.